Layer 1

Another batch of valsartan recalled over carcinogenic concerns

The MHRA has advised pharmacies to stop supplying the product and quarantine remaining stock
The MHRA has advised pharmacies to stop supplying the product and quarantine remaining stock

Pharmacies have been advised to recall an additional batch of valsartan-containing medicine which has “carcinogenic potential”, the medicines watchdog has announced.

The Medicines and Healthcare products Regulatory Agency (MHRA) issued a recall yesterday (July 10) of all batches of valsartan/hydrochlorothiazide 160/12.5mg film-coated tablets – used to treat high blood pressure and heart conditions – made by Accord Healthcare.

The alert comes after the watchdog issued a recall last week (July 6) for seven batches of valsartan-containing medicines made by Accord Healthcare and Dexcel Pharma Ltd, after an impurity was identified in their manufacturing process which “may have carcinogenic potential”.

“An investigation into other potentially impacted products is currently being undertaken and further updates will be provided as the investigation progresses,” the MHRA said.

Advice for pharmacies

The MHRA has advised pharmacies to stop supplying the product immediately, and to quarantine all remaining stock and return it to the supplier.

“If you receive queries about this issue from patients, encourage them not to stop taking their medication,” the watchdog added.

Affected batches

Accord (formerly Actavis)

  • Latest batch recalled: Valsartan/hydrochlorothiazide 160/12.5mg film-coated tablets
     
  • Valsartan 40mg, 80mg, 160mg and 320mg film-coated tablets

Dexcel Pharma Ltd

  • Valsartan 40mg, 80mg and 160mg capsules
0 Comments
Question: 
Do you stock these batches in your pharmacy?
Log in or register to post comments

Job of the week

Pharmacist
Leicester, Leicestershire
Extremely competitive salary